BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $26 from $30 and keeps a Buy rating on the shares. While ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

Hutchmed to divest its 45% equity interest in SHPL to GP Health Service Capital & Shanghai Pharma for approx. US$ 608 million: Hong Kong, Shanghai Friday, January 3, 2025, 13:00 H ...

The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.

Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the ...

Hutchmed sells 45% stake in Shanghai venture for $608M, Xgene's pain drug succeeds in Phase 2b, Hookipa buys Poolbeg Pharma, and Capricor gets $10M from Nippon Shinyaku.

In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...

Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment ...

Chinese regulators have accepted HUTCHMED's (HCM) application for priority review for the drug combination Orpathys and ...

Limited ($HK:0013), backed by Hong Kong billionaire Li Ka-Shing, gained nearly 4% today after it agreed to sell ...

Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...